Immunosuppressive anticancer drugs in man: their oncogenic potential

Area of Science:

• Oncology
• Pharmacology
• Toxicology

Background:

• Increasing cancer survival rates necessitate evaluating long-term treatment effects.
• Chemotherapeutic agents are increasingly used for non-cancerous conditions, expanding patient exposure.
• Long-range health risks associated with cancer therapies require careful consideration.

Purpose of the Study:

• To review the potential oncogenic and co-oncogenic risks of cancer chemotherapy in humans.
• To highlight the long-term hazards faced by cancer survivors and patients on chronic immunosuppressive therapy.

Main Methods:

• Literature review of existing studies on chemotherapy drug toxicity.
• Examination of experimental animal data regarding drug carcinogenicity.
• Analysis of human data on secondary malignancies post-chemotherapy.

Main Results:

• Many chemotherapy drugs demonstrate oncogenic or co-oncogenic properties in animal models.
• Evidence suggests a potential for increased cancer risk in humans undergoing chemotherapy.
• The specific mechanisms and human relevance of these oncogenic effects are areas of ongoing research.

Conclusions:

• Cancer chemotherapy, despite its benefits, carries potential long-term risks of secondary cancers.
• Further research is crucial to understand and mitigate the oncogenic potential of chemotherapeutic agents.
• Risk-benefit assessments for long-term chemotherapy use must account for potential carcinogenicity.